Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$764.00K$764.00Kderived+61.2% vs Q4 2024 Net Income-$332.00K-$332.00KderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$468,000+70.2% Operating Incomederived-$336,000N/M Operating Cash Flowderived-$456,000N/M Margins · derivedGross margin61.3%+3.2 pt vs Q4 2024
Operating margin-44.0%+103.5 pt vs Q4 2024
Net margin-43.5%+116.0 pt vs Q4 2024
ended Jul 31, 2025 · filed Oct 29, 2025 · 90 d after period end